Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

This meta-analysis investigated the comparative efficacy and safety of PARP inhibitor monotherapy as maintenance treatment in platinum sensitive recurrent ovarian cancer (ROC). Electronic databases were systematically searched for relevant RCTs. The primary endpoint was PFS. The results were stratif...

Full description

Bibliographic Details
Main Authors:	Yangchun Xu, Lei Ding, Yuan Tian, Miaomiao Bi, Ning Han, Ling Wang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-02-01
Series:	Frontiers in Oncology
Subjects:	PARP inhibitor platinum ovarian cancer network meta-analysis progress-free survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2020.573801/full

Similar Items

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
by: Michele Bartoletti, et al.
Published: (2020-05-01)

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
by: Michelle McMullen, et al.
Published: (2020-06-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer
by: Feiyue Zheng, et al.
Published: (2020-03-01)

OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer
by: Soupos Nikolaos, et al.
Published: (2015-09-01)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
by: Camilla Nero, et al.
Published: (2021-03-01)

Therapeutic applications of PARP inhibitors in ovarian cancer
by: Hongyu Xie, et al.
Published: (2020-07-01)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
by: Dockery LE, et al.
Published: (2017-06-01)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
by: Yingzhu Yang, et al.
Published: (2020-07-01)

DNA damaging agents in ovarian cancer
by: Maria-Pilar Barretina-Ginesta
Published: (2020-08-01)

Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
by: Ning Ren, et al.
Published: (2021-08-01)

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers
by: Sandy Chevrier, et al.
Published: (2021-06-01)

Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
by: Stephen M. Graves, et al.
Published: (2021-11-01)

Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer
by: Jiang X, et al.
Published: (2019-05-01)

Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020-06-01)

Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer
by: Yifan Jiang, et al.
Published: (2020-07-01)

Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis
by: Amos Stemmer, et al.
Published: (2020-10-01)

Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer
by: Xuan-zhang Huang, et al.
Published: (2020-06-01)

PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
by: D. S. Dolgasheva, et al.
Published: (2020-06-01)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
by: Eva María Guerra Alía, et al.
Published: (2019-06-01)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
by: Stergios Boussios, et al.
Published: (2019-05-01)

Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
by: Anastasia Navitski, et al.
Published: (2021-11-01)

Extending platinum-free interval in partially platinum-sensitive recurrent ovarian cancer by a non-platinum regimen: Its possible clinical significance
by: Yin-Ting Chuang, et al.
Published: (2012-09-01)

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies
by: Elizabeth K. Lee, et al.
Published: (2020-07-01)

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs
by: Luyao Wang, et al.
Published: (2017-10-01)

Olaparib as maintenance therapy and salvage therapy in recurrent ovarian cancer: The early experience in Taiwan
by: Chia-Chen Hsu, et al.
Published: (2021-07-01)

PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials
by: Yizi Wang, et al.
Published: (2020-08-01)

The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
by: Margherita Turinetto, et al.
Published: (2021-06-01)

The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients
by: Szabolcs Molnár, et al.
Published: (2021-01-01)

The evolving role of PARP inhibitors in advanced ovarian cancer
by: Levva Sofia, et al.
Published: (2021-08-01)

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
by: Alexandra S. Zimmer, et al.
Published: (2019-07-01)

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
by: Tadahiro Shoji, et al.
Published: (2018-07-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date
by: Montemorano L, et al.
Published: (2019-12-01)

PARPi after PARPi in epithelial ovarian cancer
by: K.G. Essel, et al.
Published: (2021-02-01)

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme
by: Mary-Ann Xavier, et al.
Published: (2021-08-01)

The role of PARP inhibitors in the treatment of gynecologic malignancies
by: Raquel E. Reinbolt, et al.
Published: (2013-10-01)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
by: Colombo I, et al.
Published: (2018-03-01)

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
by: Elisena Franzese, et al.
Published: (2020-06-01)

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
by: Alice Indini, et al.
Published: (2021-04-01)